This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

PharMerica Appoints Christopher Schaefer As Senior Vice President Of Corporate Development

PharMerica Corporation (NYSE: PMC), a national provider of institutional pharmacy, specialty infusion and hospital pharmacy management services, today announced that Christopher Schaefer has been appointed Senior Vice President of Corporate Development, a newly created position, effective immediately. He will report to Greg S. Weishar, Chief Executive Officer of PharMerica Corporation.

Mr. Schaefer joins PharMerica from CIT Healthcare, where he served as Director of Healthcare Investment Banking, Leveraged Finance and Mergers & Acquisitions. Prior to that, he worked in business and corporate development at Boston Heart Diagnostics. Mr. Schaeffer brings over fifteen years of experience in investment banking, and will be responsible for PharMerica’s corporate growth strategy, with a particular focus on identifying external growth opportunities.

Mr. Weishar said, "On behalf of the Board and management team, I am pleased to welcome Chris to PharMerica. He brings extensive finance and M&A experience to this new role, and I intend to work closely with him to accelerate our growth and take our company’s performance to the next level. I look forward to drawing on his expertise to advance our growth strategy and continue creating value for shareholders.”

Mr. Schaefer said, “As a strong company with an excellent reputation for its customer-centric technologies and superior pharmacy services, PharMerica is well-positioned to pursue value enhancing opportunities for its shareholders. I look forward to joining the company at this exciting time in its growth and contributing to its success.”

About Christopher Schaefer

Mr. Schaefer, 37, was previously Director of Healthcare Investment Banking, Leveraged Finance and Mergers & Acquisitions at CIT Healthcare. Prior to that, he worked at Boston Heart Diagnostics in business and corporate development. Before joining Boston Health Diagnostics, Mr. Schaefer worked in investment banking at Thomas Weisel Partners, UBS Investment Bank, Robertson Stephens and Deutsche Bank. He received a B.S. in Economics from Harvard University and an M.B.A from New York University, Stern School of Business.

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG

Markets

DOW 18,037.97 -42.17 -0.23%
S&P 500 2,108.92 -8.77 -0.41%
NASDAQ 5,060.2460 -31.8390 -0.63%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs